Pfizer Inc. (PFE) Stock Rises on $350M China Investment

Pfizer Inc. (NYSE:PFE) is on the rise, on news of a $350 million investment in China

Jun 28, 2016 at 10:18 AM
facebook twitter linkedin


Drugmaker Pfizer Inc. (NYSE:PFE) is rebounding with the broader stock market today -- not to mention some sector peers -- amid news the company plans to invest $350 million in the first biotech center in China. Plus, Pfizer's bococizumab met its primary endpoint in late-stage studies, SPIRE-HR and SPIRE-FH. At last check, PFE stock has added 1% to trade at $34.13, putting the shares' year-to-date gain at 5.7%. 

Short interest has been receding quickly on PFE. In fact, short interest fell by roughly 49% during the last two reporting periods, and now less than 1% of the stock's float is sold short. 

At the same time, there's been more pessimism than normal in the stock's options pits. By the numbers, PFE's 50-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 0.76 sits just 1 percentage point from a 12-month high, meaning put buying has been much more popular than usual. 

No matter your angle, it's a good time to buy premium on short-term PFE options. The stock's Schaeffer's Volatility Index (SVI) of 21% ranks in the 19th annual percentile. This means the options market is pricing in historically low volatility expectations at the moment. 

Taking a quick look at analysts, most are upbeat on Pfizer Inc. (NYSE:PFE). There are 15 analysts covering the shares, and nine rank them a "strong buy," while none have issued a "sell" rating. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!